Vistagen

Vistagen ($VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry

[Vistagen @Vistagen]

The @ADAA_Anxiety created a powerful video highlighting the symptoms and experiences of #SocialAnxiety. Raising awareness is key to breaking stigma and ensuring more people get the support they need. Watch and join the conversation.
#MentalHealthAwareness #ADAA

[Anxiety and Depression Association of America @ADAA_Anxiety]

Social anxiety disorder can make it hard to do everyday tasks. Our latest video created in collaboration with @Vistagen shares more about what social anxiety disorder is. https://t.co/IvjF53kNBh

#SocialAnxiety #SocialAnxietyDisorder

[Vistagen @Vistagen]

Vistagen will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. The Company will host one-on-one meetings with institutional investors during the conference. For details: https://t.co/tYE6dOXenu $VTGN

[Vistagen @Vistagen]

Vistagen today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. Read more: https://t.co/6VchQrgg6I $VTGN

[Vistagen @Vistagen]

Vistagen President and CEO, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Tuesday, May 20 at 2:35pm ET. The Company will also host one-on-one meetings during the conference. For details: https://t.co/zsG1ZyZpx4 $VTGN

[Vistagen @Vistagen]

Shawn Singh, Vistagen President and CEO, comments on the positive preliminary data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder: https://t.co/g7FIvwfHoN $VTGN

[Vistagen @Vistagen]

In the ongoing OLE portion of PALISADE-3, preliminary positive data demonstrated clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-rated scales over four months. Read more: https://t.co/g7FIvwfHoN $VTGN

[Vistagen @Vistagen]

Vistagen announced preliminary positive data from the OLE portion of its PALISADE-3 Phase 3 study showing fasedienol was well-tolerated in patients with SAD with no new drug-related safety findings after as-needed use for up to 12 months. Read more: https://t.co/g7FIvwfHoN $VTGN

[Vistagen @Vistagen]

Topline results for the randomized portion of PALISADE-4 are expected in the first half of 2026. The open label extension (OLE) portion of the PALISADE-4 study remains ongoing. Read more: https://t.co/4XriVgV1Y1 $VTGN

[Vistagen @Vistagen]

Vistagen today announced that the last patient completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, our Ph.3 trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. https://t.co/4XriVgV1Y1 $VTGN

[Vistagen @Vistagen]

Vistagen has received a “Study May Proceed” letter from @US_FDA under its U.S. IND application for refisolone nasal spray, our non-hormonal, non-systemic Ph. 2 candidate for menopausal moderate to severe vasomotor symptoms (VMS) (a.ka. “hot flashes”) https://t.co/DXbuRNLJma $VTGN

[Vistagen @Vistagen]

Tomorrow, March 17th at 9:00 AM ET, Vistagen CEO Shawn Singh will participate in a fireside chat and one-on-one meetings at the Stifel 2026 Virtual CNS Forum. Watch the live webcast here: https://t.co/YKvvu9tDMR $VTGN

[Vistagen @Vistagen]

Vistagen today announced that the Company will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026. For more details: https://t.co/T6iyyvOXlV $VTGN

[Vistagen @Vistagen]

Vistagen’s President and CEO, Shawn Singh, will present a corporate overview at the 46th Annual TD Cowen Healthcare Conference on Monday, March 2, at 3:50 p.m. ET. For more information: https://t.co/YOvnJ81kXn $VTGN

[Vistagen @Vistagen]

The PALISADE-4 Phase 3 trial of fasedienol for acute treatment of Social Anxiety Disorder is proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026. See Vistagen's corporate update here: https://t.co/aYZzRDB3tR $VTGN

[Vistagen @Vistagen]

Vistagen today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. Read more: https://t.co/aYZzRDB3tR $VTGN

[Vistagen @Vistagen]

Vistagen will host a conference call and webcast today at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. Join here: https://t.co/zGBdmDdhiq $VTGN

[Vistagen @Vistagen]

Vistagen will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. For details: https://t.co/6nq2NW1mai $VTGN

[Vistagen @Vistagen]

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder: https://t.co/Dz5cYmaeuj $VTGN

[Vistagen @Vistagen]

Social anxiety disorder is a profound fear of being watched, judged, or embarrassed, even in everyday situations like school or work. Hear our CEO, Shawn Singh, discuss the impacts of social anxiety disorder on the
Inside Biotech podcast. $VTGN

[Vistagen @Vistagen]

Vistagen is pleased to announce the appointment of Nick Tressler as CFO, effective today. Mr. Tressler brings over 20 years of financial leadership experience in the life sciences industry guiding companies through pivotal growth and transformation. https://t.co/kO2KsZd8f2 $VTGN

[Vistagen @Vistagen]

Exploratory data presented at @MenopauseOrg 2025 Annual Meeting demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) due to menopause. Read more: https://t.co/bEO4rvKCpL $VTGN